Product Overview: Duzela
Duzela 60 mg is a duloxetine hydrochloride formulation developed by Sun Pharmaceuticals Industries for comprehensive laboratory investigations into dual neurotransmitter pathway modulation. This selective serotonin-norepinephrine reuptake inhibitor (SNRI) provides researchers with a standardised pharmaceutical-grade compound to examine the complex interactions between serotonergic and noradrenergic systems in controlled experimental conditions. The precise 60 mg dosage offers consistent analytical parameters for dose-response studies and comparative research protocols examining neurochemical pathway inhibition mechanisms.
Research teams at Stroid UK Shop investigate duloxetine’s dual-mechanism action across multiple neurotransmitter systems, providing valuable insights into synaptic modulation and reuptake transporter selectivity. Laboratory studies demonstrate duloxetine’s balanced inhibition of both serotonin and norepinephrine reuptake transporters, making it an essential reference compound for comparative SNRI research. The Sun Pharmaceuticals formulation ensures consistent bioavailability profiles and standardised analytical outcomes across experimental protocols examining neurotransmitter reuptake mechanisms and synaptic transmission dynamics.
Research Applications
Laboratory investigations utilise Duzela 60 mg to examine serotonin-norepinephrine reuptake inhibition kinetics, receptor binding affinity studies, and neurotransmitter pathway modulation mechanisms in controlled research environments. Research protocols explore duloxetine’s selectivity ratios between serotonin and norepinephrine transporters, providing comparative data for SNRI classification studies and pharmaceutical development research. Advanced analytical methods investigate the compound’s pharmacokinetic properties, metabolism pathways, and tissue distribution patterns in preclinical research models.
Comparative studies examine duloxetine alongside other antidepressant compounds to establish selectivity profiles and mechanism-of-action differences across neurotransmitter systems. Research teams analyse the compound’s effects on synaptic neurotransmitter concentrations, reuptake transporter occupancy rates, and downstream signalling cascade activation in neurochemical research protocols. Laboratory investigations also explore duloxetine’s secondary pharmacological effects, including interactions with other neurotransmitter systems and potential off-target binding activities that contribute to its overall pharmacological profile.
Researchers studying selective receptor modulators and bioactive peptides utilise duloxetine as a reference standard for comparative neuropharmacology studies examining different receptor modulation mechanisms and their effects on neurotransmitter system function.
Specifications
| Parameter | Value |
|---|---|
| Active Ingredient | Duloxetine Hydrochloride |
| Strength | 60 mg |
| Manufacturer | Sun Pharmaceuticals Industries |
| Formulation | Enteric-coated capsules |
| CAS Number | 136434-34-9 |
| Molecular Formula | C₁₈H₁₉NOS·HCl |
| Molecular Weight | 333.88 g/mol |
| Storage | Room temperature, dry conditions |
Research Compliance
Duzela 60 mg is supplied exclusively for in-vitro research applications and analytical testing purposes. This pharmaceutical compound is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must maintain appropriate laboratory safety protocols and comply with institutional guidelines when handling this material. All experimental procedures should be conducted in controlled laboratory environments by qualified personnel with proper analytical equipment and safety measures in place.
